ClinicalTrials.Veeva

Menu

Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon (NivOSe)

Grenoble Alpes University Hospital Center (CHU) logo

Grenoble Alpes University Hospital Center (CHU)

Status

Unknown

Conditions

Raynaud Phenomenon

Treatments

Dietary Supplement: Beetroot juice
Dietary Supplement: L-citrulline
Dietary Supplement: Denitrated beetroot juice
Dietary Supplement: L-citrulline placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT03749577
38RC17.270

Details and patient eligibility

About

The investigators aim at comparing the efficacy of a 2 weeks supplementation by L-citrulline or beetroot juice to L-citrulline placebo or denitrated beetroot juice respectively on Raynaud's phenomenon severity. Raynaud's phenomenon severity will be assessed through the Raynaud Condition Score, daily frequency of attacks or cumulative attack duration (expressed as min) daily collected by patients in a diary. Each Volunteer will choose his own main outcome among these 3 criteria.

Full description

Raynaud's phenomenon (RP) is a clinical condition that follows an exaggerated vasoconstriction of extremities in response to a cold or emotional stress. Microvascular dysfunction and alteration of the endothelial NO-dependent vasodilatation pathway through NO synthases (NOS) represents one of the main mechanisms.

A pharmacological treatment in RP is proposed to patients when conservative measures are not efficient enough to control the symptoms: calcium channel blockers remains the first line, phosphodiesterase type 5 inhibitors as a second line treatment, while intravenous iloprost remains restricted to patients with digital ischaemia. Vasodilator therapies are commonly associated with side effects due to the non-specific systemic vasodilation that often result in permanent discontinuation. Many patients prefer complementary and alternative therapies, but none has proven its efficacy. Therefore, there is still room for improvement in the treatment of RP, and research is needed in this area.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • BMI > 18

  • Active Raynaud's Phenomenon characterized by a clinical history of Raynaud's

    1. Primary RP or secondary to limited (LSSc), limited or diffuse cutaneous scleroderma (lcSSc or dcSSc) according to the criteria of Leroy and Medsger.
    2. At least 1 RP attacks per week and a specific finger patient picture in RP attack (assessed over the 2 weeks preceding inclusion)
  • Stable disease over the previous two months (i.e. recent diagnosis of SSc will be excluded)

  • Patients insured by a social security scheme or beneficiaries of such a scheme

  • Patients who have dated and signed the informed consent form

Exclusion criteria

  • Uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled angina
  • Haemodynamic instability
  • Pregnancy (or considering pregnancy in next 4 months) or breast feeding
  • Subject in an exclusion period from another study,
  • Subject under administrative or judicial supervision
  • Subject not able to be contacted in case of emergency

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

30 participants in 4 patient groups, including a placebo group

L-citrulline
Experimental group
Description:
Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods. A 7 days wash-out period will be imposed between treatment periods (placebo and treatment).
Treatment:
Dietary Supplement: L-citrulline
Beetroot juice
Experimental group
Description:
Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods. A 7 days wash-out period will be imposed between treatment periods (placebo and treatment).
Treatment:
Dietary Supplement: Beetroot juice
L-citrulline placebo
Placebo Comparator group
Description:
Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods. A 7 days wash-out period will be imposed between treatment periods (placebo and treatment).
Treatment:
Dietary Supplement: L-citrulline placebo
Denitrated beetroot juice
Placebo Comparator group
Description:
Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods. A 7 days wash-out period will be imposed between treatment periods (placebo and treatment).
Treatment:
Dietary Supplement: Denitrated beetroot juice

Trial contacts and locations

1

Loading...

Central trial contact

Adeline Paris; Charles Khouri

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems